tominersen: Clinical Trials

4 completed, 1 active not recruiting. 2 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	2	Active not recruiting 1, Completed 1
Phase 3	2	Completed 2
Phase 1	1	Completed 1

Follow tominersen: new trials by email Literature Review of tominersen trials Research Report on tominersen

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease Tominersen, Placebo - Huntington Disease	Phase 2	Active not recruiting	Hoffmann-La Roche	301	2023-02-03	2026-08-10
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease RO7234292 (RG6042) - Huntingtons Disease	Phase 1	Completed	Hoffmann-La Roche	12	2019-09-02	2024-10-03
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies RO7234292 (RG6042) - Huntington Disease	Phase 3	Completed	Hoffmann-La Roche	236	2019-04-23	2023-08-31
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease RO7234292, Placebo - Huntingtons Disease	Phase 3	Completed	Hoffmann-La Roche	899	2019-01-23	2024-03-01
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) RO7234292 (RG6042) - Huntington's Disease	Phase 2	Completed	Hoffmann-La Roche	46	2018-01-02	2022-03-24

Conditions studied

Huntington Disease (3)  ·  Chorea (2)

Sponsors

Hoffmann-La Roche (5)

Countries

United Kingdom (5)  ·  Canada (4)  ·  Germany (4)  ·  Austria (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Spain (3)  ·  United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Denmark (2)  ·  France (2)  ·  New Zealand (2)  ·  Poland (2)  ·  Switzerland (2)

Results publications

PMID 30776019, PMID 31381524, PMID 38055260, PMID 42032152

NIH funding

2018 (1), 2023 (1)